Peritoneal Dialysis in Congestive Heart Failure (PDinCHF)
Primary Purpose
Congestive Heart Failure
Status
Terminated
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
icodextrin
Sponsored by
About this trial
This is an interventional treatment trial for Congestive Heart Failure focused on measuring Congestive Heart Failure, Peritoneal Dialysis, Symptomatic improvement, Renal function
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years
- Refractory Left Ventricular Congestive Heart Failure: LVEF < 30%
- Diminished renal function: eGFR < 60 ml/min
- Clinically volume overloaded (Dyspnoea (NYHA III-IV), edema, and/or ascites)
- Hospitalization for CHF during the last 6 months
- Patient is on optimal cardiologic medical therapy, which has been stable for more than 4 weeks
- Suitable for PD
Exclusion Criteria:
- Hypotension (SBP < 100 mmHg / MAP < 70) mmHg
- Instable AP or recent (< 6 months) myocardial infarction.
- Contraindications for PD (e.g. visual handicap, social)
- Liver failure
- COPD Gold class IV
- Malignancy with life expectancy < 2 years
- Non compliance
- No informed consent
- Poor mental health
Sites / Locations
- Martini Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Sham Comparator
Active Comparator
Active Comparator
Arm Label
Standard Care
2 Icodextrin PD changes / day
1 Icodextrin PD change/day
Arm Description
Outcomes
Primary Outcome Measures
Number of patients in NYHA class I, II, III, or IV as measure of quality of life
Secondary Outcome Measures
Quality of life measures
Reduction in unfavorable days. Short-Form 36. Minnesota Living with Heart failure Questionnaire. 6 minute walk test. (re)hospitalization. Survival. Medication optimalisation. Cardial: LVH. Renal: GFR/ERPF/FF; KIM-1, NGAL, NAG. Volume status: ECV (radioactive and bio-impedance). Neurohumoral and inflammatory parameters.
Full Information
NCT ID
NCT01124227
First Posted
May 12, 2010
Last Updated
August 15, 2019
Sponsor
Martini Hospital Groningen
Collaborators
Baxter Healthcare Corporation, Roche BV Netherlands
1. Study Identification
Unique Protocol Identification Number
NCT01124227
Brief Title
Peritoneal Dialysis in Congestive Heart Failure
Acronym
PDinCHF
Official Title
Symptomatic Improvement by Peritoneal Dialysis in Patients With End Stage Congestive Heart Failure
Study Type
Interventional
2. Study Status
Record Verification Date
August 2019
Overall Recruitment Status
Terminated
Why Stopped
Due to very specific inclusion criteria the anticipated number of patients was not reached. Inclusion stopped at N=26, allowing for analyzing primary outcomes.
Study Start Date
April 2010 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Martini Hospital Groningen
Collaborators
Baxter Healthcare Corporation, Roche BV Netherlands
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Rationale: End-stage congestive heart failure is a serious invalidating condition with a poor prognosis and increasing incidence. Non-randomized observations showed peritoneal dialysis (PD) in these patients to improve clinically from NYHA stadium III-IV to as low as NYHA stadium I-II. A randomized trial is needed to test whether PD improves symptoms in this condition and to find an optimal scheme.
Objective: To improve symptomatology in severe chronic failure patients. Study design: Open, parallel intervention trial comparing 2 schemes of peritoneal dialysis with icodextrin (Extraneal®) with standard medical therapy..
Study population: Patients with chronic refractory left ventricular congestive heart failure (LVEF < 30%, older than 18 years).
Intervention: Peritoneal dialysis with one (night) or two (night and day) dwells with icodextrin (Extraneal®).
Main study parameters/endpoints: Reduction in NYHA classification of symptomatic Congestive Heart Failure at 8 months after start of PD therapy. Burden of congestive heart failure: measured by reduction in unfavorable days (noted by patients in diaries and including days of hospitalization for CHF-deterioration and death).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congestive Heart Failure
Keywords
Congestive Heart Failure, Peritoneal Dialysis, Symptomatic improvement, Renal function
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard Care
Arm Type
Sham Comparator
Arm Title
2 Icodextrin PD changes / day
Arm Type
Active Comparator
Arm Title
1 Icodextrin PD change/day
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
icodextrin
Other Intervention Name(s)
Extraneal, RVG 21300
Intervention Description
2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
Primary Outcome Measure Information:
Title
Number of patients in NYHA class I, II, III, or IV as measure of quality of life
Time Frame
8 months
Secondary Outcome Measure Information:
Title
Quality of life measures
Description
Reduction in unfavorable days. Short-Form 36. Minnesota Living with Heart failure Questionnaire. 6 minute walk test. (re)hospitalization. Survival. Medication optimalisation. Cardial: LVH. Renal: GFR/ERPF/FF; KIM-1, NGAL, NAG. Volume status: ECV (radioactive and bio-impedance). Neurohumoral and inflammatory parameters.
Time Frame
8 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 18 years
Refractory Left Ventricular Congestive Heart Failure: LVEF < 30%
Diminished renal function: eGFR < 60 ml/min
Clinically volume overloaded (Dyspnoea (NYHA III-IV), edema, and/or ascites)
Hospitalization for CHF during the last 6 months
Patient is on optimal cardiologic medical therapy, which has been stable for more than 4 weeks
Suitable for PD
Exclusion Criteria:
Hypotension (SBP < 100 mmHg / MAP < 70) mmHg
Instable AP or recent (< 6 months) myocardial infarction.
Contraindications for PD (e.g. visual handicap, social)
Liver failure
COPD Gold class IV
Malignancy with life expectancy < 2 years
Non compliance
No informed consent
Poor mental health
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wilbert M Janssen, MD, PhD
Organizational Affiliation
Martini Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Martini Hospital
City
Groningen
ZIP/Postal Code
9700 RM
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
Peritoneal Dialysis in Congestive Heart Failure
We'll reach out to this number within 24 hrs